Millennium Management LLC Has $1.70 Million Holdings in Prothena Co. plc (NASDAQ:PRTA)

Millennium Management LLC increased its stake in Prothena Co. plc (NASDAQ:PRTA) by 9.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 123,005 shares of the biotechnology company’s stock after purchasing an additional 10,467 shares during the period. Millennium Management LLC owned approximately 0.23% of Prothena worth $1,704,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Virtus ETF Advisers LLC boosted its stake in Prothena by 19.3% in the 4th quarter. Virtus ETF Advisers LLC now owns 5,148 shares of the biotechnology company’s stock worth $71,000 after purchasing an additional 833 shares during the period. China Universal Asset Management Co. Ltd. boosted its stake in Prothena by 10.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,409 shares of the biotechnology company’s stock worth $158,000 after purchasing an additional 1,065 shares during the period. Rhumbline Advisers boosted its stake in Prothena by 1.8% in the 4th quarter. Rhumbline Advisers now owns 67,115 shares of the biotechnology company’s stock worth $930,000 after purchasing an additional 1,175 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Prothena by 6.0% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 27,269 shares of the biotechnology company’s stock worth $381,000 after purchasing an additional 1,551 shares during the period. Finally, Invesco Ltd. boosted its stake in Prothena by 4.0% in the 4th quarter. Invesco Ltd. now owns 42,846 shares of the biotechnology company’s stock worth $593,000 after purchasing an additional 1,632 shares during the period. 97.08% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

PRTA has been the subject of a number of recent research reports. HC Wainwright reduced their price objective on shares of Prothena from $30.00 to $14.00 and set a “buy” rating for the company in a research note on Tuesday, May 27th. Chardan Capital reduced their price objective on shares of Prothena from $40.00 to $18.00 and set a “buy” rating for the company in a research note on Tuesday, May 27th. Jefferies Financial Group downgraded shares of Prothena from a “buy” rating to a “hold” rating and set a $6.00 price objective for the company. in a research note on Tuesday, May 27th. Wall Street Zen upgraded shares of Prothena from a “sell” rating to a “hold” rating in a research note on Monday, February 24th. Finally, Bank of America restated an “underperform” rating on shares of Prothena in a research note on Wednesday, May 28th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $31.50.

Prothena Stock Up 1.5%

Prothena stock opened at $4.66 on Tuesday. The stock has a market cap of $250.83 million, a P/E ratio of -2.03 and a beta of 0.11. Prothena Co. plc has a twelve month low of $4.32 and a twelve month high of $25.42. The company’s 50-day moving average price is $8.70 and its two-hundred day moving average price is $12.36.

Prothena (NASDAQ:PRTA) last released its quarterly earnings results on Thursday, May 8th. The biotechnology company reported ($1.12) earnings per share for the quarter, missing the consensus estimate of ($0.92) by ($0.20). The company had revenue of $2.83 million during the quarter, compared to the consensus estimate of $8.18 million. Prothena had a negative net margin of 90.50% and a negative return on equity of 22.67%. The firm’s revenue was up 5500.0% compared to the same quarter last year. During the same period in the prior year, the company earned ($1.34) earnings per share. Equities analysts anticipate that Prothena Co. plc will post -4.04 earnings per share for the current fiscal year.

Prothena Profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson’s disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer’s disease.